 24 Jun 2020 - Immutep ASX:IMM CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer MBC, its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies. 